Evidence map›Paper›PMID 35052736›Full record

ArticleBiomedicines2021

Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury.

Estefanía Caballano-Infantes, Alberto García-García, Carlos Lopez-Gomez, Alejandro Cueto, Mercedes Robles-Diaz, Aida Ortega-Alonso, Flores Martín-Reyes, Ismael Alvarez-Alvarez, Isabel Arranz-Salas, Francisco Ruiz-Cabello and 4 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Estefanía Caballano-InfantesDepartamento de Farmacología, Facultad de Medicina, Universidad de Málaga, 29010 Málaga, Spain.ORCID 0000-0001-8269-9158
Alberto García-GarcíaUGC de Aparato Digestivo, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, 29010 Málaga, Spain.ORCID 0000-0003-0851-6442
Carlos Lopez-GomezUGC de Aparato Digestivo, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, 29010 Málaga, Spain.ORCID 0000-0003-2699-451X
Alejandro CuetoDepartamento de Farmacología, Facultad de Medicina, Universidad de Málaga, 29010 Málaga, Spain.
Mercedes Robles-DiazUGC de Aparato Digestivo, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, 29010 Málaga, Spain.
Aida Ortega-AlonsoUGC de Aparato Digestivo, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, 29010 Málaga, Spain.
Flores Martín-ReyesUGC de Aparato Digestivo, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, 29010 Málaga, Spain.ORCID 0000-0002-3633-8367
Ismael Alvarez-AlvarezUGC de Aparato Digestivo, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, 29010 Málaga, Spain.ORCID 0000-0001-6271-0604
Isabel Arranz-SalasInstituto de Investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain.
Francisco Ruiz-CabelloServicio de Análisis Clínicos e Inmunología, UGC de Laboratorio Clínico, Hospital Universitario Virgen de las Nieves, Departamento de Bioquímica y Biología Molecular II/Inmunología, Facultad de Medicina, Universidad de Granada, 18014 Granada, Spain.ORCID 0000-0002-2247-3293
Isabel M LucenaDepartamento de Farmacología, Facultad de Medicina, Universidad de Málaga, 29010 Málaga, Spain.ORCID 0000-0001-9586-4896
Eduardo García-FuentesUGC de Aparato Digestivo, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, 29010 Málaga, Spain.ORCID 0000-0002-3491-2724
Raúl J AndradeUGC de Aparato Digestivo, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, 29010 Málaga, Spain.ORCID 0000-0002-1565-0757
Miren García-CortesUGC de Aparato Digestivo, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, 29010 Málaga, Spain.ORCID 0000-0003-0410-8273
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESHospital Clínico Universitario Virgen de la Victoria · ESInstituto de Investigación Biomédica de Málaga · ESSpanish Clinical Research Network · ESUniversidad de Granada · ESUniversidad de Málaga · ES

Funding

Consejería de Economía, Conocimiento, Empresas y Universidad (Junta de Andalucía, Spain) PI18-RT-3364Consejería de Economía, Conocimiento, Empresas y Universidad (Junta de Andalucía, Spain) UMA18-FEDERJA-194Consejería de Salud (Junta de Andalucía, Spain) PI-0285-2016Instituto de Salud Carlos III PI18/01804Instituto de Salud Carlos III PI19/00883Instituto de Salud Carlos III PI21/01248
6 · The paper itself

Abstract

backgroundNon-alcoholic fatty liver disease (NAFLD) and idiosyncratic drug-induced liver injury (DILI) could share molecular mechanisms involving the immune system. We aimed to identify activation immunological biomarkers in invariant natural killer T (iNKT) and CD4/CD8+ T cells in NAFLD and DILI.

methodsWe analyzed the activation profile (CD69, CD25, and HLA-DR) and natural killer group 2 member D (NKG2D) on iNKT cells, and CD4/CD8 T cells in peripheral blood mononuclear cells from NAFLD, with or without significant liver fibrosis, and DILI patients.

resultsThere was an increase in iNKT cells in NAFLD patients compared to DILI or control subjects. Regarding the cellular activation profile, NAFLD with significant liver fibrosis (F ≥ 2) displayed higher levels of CD69+iNKT cells compared to NAFLD with none or mild liver fibrosis (F ≤ 1) and control patients. CD69+iNKT positively correlated with insulin resistance, aspartate aminotransferase (AST) level, liver fibrosis-4 index (FIB4) and AST to Platelet Ratio Index (APRI). DILI patients showed an increase in CD69+ and HLA-DR+ in both CD4+ and CD8+ T cells, detecting the most relevant difference in the case of CD69+CD8+ T cells.

conclusionsCD69+iNKT may be a biomarker to assess liver fibrosis progression in NAFLD. CD69+CD8+ T cells were identified as a potential distinctive biomarker for distinguishing DILI from NAFLD.

Indexed as

drug-induced liver injury (DILI)immune responseimmunophenotypeliver fibrosisnon-alcoholic fatty liver disease (NAFLD)

Identifiers

PMID35052736
PMCPMC8772872
OpenAlexW4200597342

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.